Enliven Therapeutics, Inc. NASDAQ:ELVN

Enliven Therapeutics stock price today

$19.76
-2.60
-11.67%
Financial Health
0
1
2
3
4
5
6
7
8
9

Enliven Therapeutics stock price monthly change

-9.58%
month

Enliven Therapeutics stock price quarterly change

-9.58%
quarter

Enliven Therapeutics stock price yearly change

+50.94%
year

Enliven Therapeutics key metrics

Market Cap
1.05B
Enterprise value
N/A
P/E
-22.72
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
5.69
PEG ratio
-0.22
EPS
-1.93
Revenue
N/A
EBITDA
-92.79M
Income
-79.59M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Enliven Therapeutics stock price history

Enliven Therapeutics stock forecast

Enliven Therapeutics financial statements

Average Price Target
Last Year

$39.5

Potential upside: 99.89%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Enliven Therapeutics, Inc. (NASDAQ:ELVN): Profit margin
Jun 2023 0 -16.72M
Sep 2023 0 -20.76M
Dec 2023 440K -19.37M -4402.27%
Mar 2024 0 -22.73M
Enliven Therapeutics, Inc. (NASDAQ:ELVN): Debt to assets
Jun 2023 288501000 9.50M 3.3%
Sep 2023 274041000 12.29M 4.49%
Dec 2023 271867000 25.96M 9.55%
Mar 2024 342777000 25.06M 7.31%
Enliven Therapeutics, Inc. (NASDAQ:ELVN): Cash Flow
Jun 2023 -12.04M -151.51M -2.82M
Sep 2023 -15.89M -35.54M -425K
Dec 2023 -12.48M 38.68M 90K
Mar 2024 -23.36M -17.88M 90.27M

Enliven Therapeutics alternative data

Enliven Therapeutics, Inc. (NASDAQ:ELVN): Employee count
Aug 2023 29
Sep 2023 37
Oct 2023 37
Nov 2023 37
Dec 2023 44
Jan 2024 44
Feb 2024 44
Mar 2024 46
Apr 2024 46
May 2024 46
Jun 2024 50
Jul 2024 50

Enliven Therapeutics other data

13.78% +13.78%
of ELVN is owned by hedge funds
3.63M +3.63M
shares is hold by hedge funds

Enliven Therapeutics, Inc. (NASDAQ:ELVN): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 533395
Feb 2024 0 846395
Mar 2024 0 34673
Apr 2024 0 254020
May 2024 0 2103362
Jun 2024 0 18653
Jul 2024 0 104231
Aug 2024 0 29520
Sep 2024 0 7520
Oct 2024 0 146319
Nov 2024 0 5250
Transaction Date Insider Security Shares Price per share Total value Source
Option
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Stock Option (right to buy) 5,250 $2.48 $13,020
Option
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Common Stock 5,250 $2.48 $13,020
Sale
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Common Stock 4,250 $24.78 $105,315
Sale
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Common Stock 1,000 $25.38 $25,376
Option
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Stock Option (right to buy) 6,250 $2.48 $15,500
Option
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Common Stock 6,250 $2.48 $15,500
Sale
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Common Stock 5,600 $28.49 $159,561
Sale
HOHL BENJAMIN officer: CHIEF FINANCIAL OFFICER
Common Stock 650 $29.11 $18,922
Sale
PATEL ANISH officer: CHIEF OPERATING OFFICER
Common Stock 716 $30 $21,483
Sale
LYSSIKATOS JOSEPH P officer: CHIEF SCIENTIFIC OFFICER
Common Stock 847 $30 $25,413
Wednesday, 13 November 2024
prnewswire.com
Thursday, 7 November 2024
prnewswire.com
Friday, 18 October 2024
youtube.com
Monday, 14 October 2024
zacks.com
Saturday, 28 September 2024
globenewswire.com
Thursday, 26 September 2024
zacks.com
Wednesday, 18 September 2024
globenewswire.com
Wednesday, 4 September 2024
zacks.com
Friday, 16 August 2024
zacks.com
Wednesday, 29 May 2024
globenewswire.com
Tuesday, 14 May 2024
globenewswire.com
Thursday, 11 April 2024
Proactive Investors
Tuesday, 27 February 2024
GlobeNewsWire
Friday, 18 August 2023
Seeking Alpha
Wednesday, 31 May 2023
GlobeNewsWire
Friday, 24 March 2023
Investors Business Daily
  • What's the price of Enliven Therapeutics stock today?

    One share of Enliven Therapeutics stock can currently be purchased for approximately $19.76.

  • When is Enliven Therapeutics's next earnings date?

    Unfortunately, Enliven Therapeutics's (ELVN) next earnings date is currently unknown.

  • Does Enliven Therapeutics pay dividends?

    No, Enliven Therapeutics does not pay dividends.

  • How much money does Enliven Therapeutics make?

    Enliven Therapeutics has a market capitalization of 1.05B.

  • What is Enliven Therapeutics's stock symbol?

    Enliven Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ELVN".

  • What is Enliven Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Enliven Therapeutics?

    Shares of Enliven Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Enliven Therapeutics have?

    As Jul 2024, Enliven Therapeutics employs 50 workers, which is 9% more then previous quarter.

  • When Enliven Therapeutics went public?

    Enliven Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 12 Mar 2020.

  • What is Enliven Therapeutics's official website?

    The official website for Enliven Therapeutics is enliventherapeutics.com.

  • Where are Enliven Therapeutics's headquarters?

    Enliven Therapeutics is headquartered at 6200 Lookout Road, Boulder, CO.

  • How can i contact Enliven Therapeutics?

    Enliven Therapeutics's mailing address is 6200 Lookout Road, Boulder, CO and company can be reached via phone at +7 206478519.

  • What is Enliven Therapeutics stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Enliven Therapeutics in the last 12 months, the avarage price target is $39.5. The average price target represents a 99.89% change from the last price of $19.76.

Enliven Therapeutics company profile:

Enliven Therapeutics, Inc.

enliventherapeutics.com
Exchange:

NASDAQ

Full time employees:

46

Industry:

Biotechnology

Sector:

Healthcare

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

6200 Lookout Road
Boulder, CO 80301

CIK: 0001672619
ISIN: US29337E1029
CUSIP: 29337E102